Summary
Amgen Inc. reported strong financial performance in 2003, driven by significant growth in its key products, particularly Aranesp®, Neulasta®, and ENBREL®. Total revenues surged by 58% to $7.87 billion, largely due to the successful integration of Immunex and robust demand for its new biologics. The company's strategic focus on expanding its product pipeline and manufacturing capabilities is evident in its substantial capital expenditures, including investments in new manufacturing plants in Rhode Island and Puerto Rico. While Amgen faces ongoing legal proceedings and investigations related to drug pricing and patent disputes, management stated that these are not expected to have a material adverse effect on its financial statements. The company maintains a strong liquidity position and continues to invest in research and development to fuel future growth.
Key Highlights
- 1Total revenues increased by 58% to $7.87 billion in 2003, primarily driven by Aranesp®, Neulasta®, and ENBREL®.
- 2The acquisition of Immunex in July 2002 significantly contributed to revenue growth, with ENBREL® sales reaching $1.3 billion in 2003.
- 3Capital expenditures increased significantly in 2003 to $1.36 billion, reflecting investments in manufacturing capacity, including new plants in Rhode Island and Puerto Rico.
- 4Amgen repurchased $1.8 billion of its common stock in 2003 under its stock repurchase program.
- 5The company reported a net income of $2.26 billion in 2003, a significant turnaround from a net loss of $1.39 billion in 2002, which was impacted by a $2.99 billion write-off of acquired in-process R&D.
- 6Amgen is involved in several legal proceedings, including patent litigation with Transkaryotic Therapies and Aventis, and investigations related to drug pricing practices, though the company does not believe these will materially adversely affect its financial statements.
- 7Cash provided by operating activities increased to $3.57 billion in 2003, demonstrating strong operational cash generation.